**4.6. CAR-T cells and anti-PD1/anti-PDL1**

CAR-T cells, which are being developed in lymphoid hemopathies of immunocompetent patients, have not yet been used in an immunocompromised context that could potentially reduce their effectiveness.

Anti-PD1/PDL1 antibodies by improving immunity expose patients to rejection of the transplanted organ, sometimes abruptly; their indication in PTLDs, mainly of Hodgkin type, is strongly discouraged and should only be proposed by the last resort [24].
